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Durability of carotid endarterectomy
Ecker RD, Pichelmann MA, Meissner I, Meyer FB. Stroke 2003;34:2941-4.
Conclusion: In a consecutive series of 1000 carotid endarterectomies
(CEAs), the authors had a 30-day all stroke and death rate of 1.9% and a
recurrent stenosis rate (70% stenosis) in the operated artery of 0.1%, with
a mean time to recurrence of 4  2 years.
Summary: This is a report of 1000 consecutive CEAs from the De-
partment of Neurosurgery at the Mayo Clinic. There were 680 men, 320
women, aged 69  8 years. Follow-up averaged 7.1 years (range, 2 to 11
years). Symptomatic internal carotid artery stenosis was present in 59% of the
patients. All CEAs were performed with preoperative aspirin, intraoperative
heparin, intraoperative EEG monitoring, and selective shunting based on
EEG changes. Routine patch closure was used.
The combined 30-day all stroke and death rate was 1.9%. There were
9 deaths (0.9%); 6 were neurologic and 3 were cardiac. There were 10
strokes (1.0%). Of the 10 strokes, 7 made good recovery. Recurrent
internal carotid artery stenosis of 70% as documented by duplex
scanning was found in only 10 patients (0.1%). The mean time to
recurrence was 4  2 years and only 2 of the recurrences were
symptomatic.
Comment: This is another of a number of large, single institutional
series of carotid endarterectomies documenting excellent short-term mor-
bidity and mortality and long-term durability of CEA. This, and similar
studies, have likely been stimulated by the increasing “visibility” of carotid
stenting. The results of this study, however, while excellent, will have
absolutely no impact on the debate of CEA versus carotid stenting. A
properly performed randomized trial is required.
Effects of Benzafibrate and Simvastatin on endothelial activation and
lipid peroxidation in hypercholesterolemia: Evidence of different vas-
cular protection by different lipid-lowering treatments
Desideri G, Groce G, Tucci M, et al. J Endocrinol Metab 2003;88:5341-7.
Conclusion: Circulating levels of endothelial adhesion molecules in
hypercholesterolemic patients are decreased with Simvastatin but not Ben-
zafibrate.
Summary: Endothelial adhesion molecule–mediated leukocyte adhe-
sion and transendothelial migration are fundamental steps in atherogen-
esis. The authors studied the effects in hypercholesterolemic patients of
two lipid-lowering agents on circulating levels of endothelial adhesion
molecules. Never-treated hypercholesterolemic outpatients (n 67) and
32 controls matched for sex, age, blood pressure, inflammatory indexes,
and acute phase reactive proteins were studied. Hypercholesterolemic
patients were divided into four groups. Group 1 was treated with
simvastatin (40mg/d), group 2 received benzafibrate (80mg/d), group
3 was treated with simvastatin plus vitamin E, and group 4 was treated
with benzafibrate plus vitamin E. Circulating levels of intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1), and E-selectin were evaluated at baseline in all four patient groups and
controls, and in the four patient groups following 1, 3, 4, and 6 months
of treatment.
Circulating ICAM-1, VCAM-1, and E-selectin levels were higher in the
hypercholesterolemic patient groups (groups 1-4) than in control subjects.
Both simvastatin (group 1) and benzafibrate (group 2), significantly reduced
total and low-density lipoprotein (LDL) cholesterol concentrations (P 
.0001). Simvastatin treatment was more effective than benzafibrate. Vitamin
E supplementation did not further reduce total or LDL cholesterol levels in
either simvastatin- or benzafibrate-treated patients.
Plasma ICAM-1, VCAM-1, and E-selectin significantly decreased dur-
ing the 6 months of the simvastatin treatment (P  .0001). There was no
decrease in endothelial adhesion molecule levels in patients treated with
benzafibrate alone. The addition of vitamin E resulted in further decreases in
endothelial adhesion molecules in patients treated with simvastatin and in a
decrease in endothelial adhesion molecules in the patients treated with
benzafibrate (P  .0003 to P  .0001).
Comment: The data demonstrate drug-induced cholesterol lowering
is not necessarily associated with a reduction of endothelial activation in
hypercholesterolemic patients. The beneficial effects of statin therapy in
treatment of patients with hypercholesterolemia may be independent of, or
additive to, cholesterol-lowering effects.
Measures of obesity are associated with vascular stiffness in young and
older adults
Wildman RP, MacKey RH, Bostom A, et al. Hypertension 2003;42:468-73.
Conclusion: Measures of excess body weight are associated with
increased levels of aortic stiffness in both African American and white
populations, in both older subjects and subjects as young as 20 to 30 years of
age.
Summary: Aortic pulse-wave velocity (aPWV) is a measure of aortic
stiffness. Arterial stiffening predisposes patients to hypertension and aging of
the vascular system. In this study, the association between aPWV and
measures of obesity was determined in 186 younger adults (20 to 40 years)
and 177 older adults (41 to 70 years). Measures of obesity evaluated
included body weight, body mass index (BMI), waist and hip circumfer-
ences, and waist-to-hip ratio.
Median aPWV was 627cm/s for older adults and 468cm/s for younger
adults (P  .001). Higher pulse-wave velocity correlated with higher levels
of all measures of obesity (p  0.01 for all measures). Twenty- to 30-year-
old obese individuals (BMI 30) had an aPWV 47cm/s higher than that of
nonobese individuals (P  .001). In all cases, obesity measurements were
strong independent predictors of aPWV. Results were consistent by race
even in individuals as young as 20 to 30 years of age.
Comment: The precise mechanism whereby excess weight adversely
affects the cardiovascular system is unknown. It is known, however, that
increased arterial stiffness predisposes to hypertension, which is a strong risk
factor for vascular disease. This study suggests one mechanism for an
increased risk of vascular disease in young obese patients as they age.
Endovascular stent graft repair of abdominal and thoracic aortic aneu-
rysms: A 10-year experience with 817 patients
Marin ML, Hollier LH, Ellozy SH, et al. Annals of Surgery 2003;238:586-
95.
Conclusion: A total of 817 patients were treated with abdominal aortic
(AA) or thoracic aortic (TA) stent grafts. Initial technical success was 93.8%,
perioperative mortality was 2.3%, primary clinical success was 65  6% at 8
years, and 5-year survival was 47  4%.
Summary: This is the experience of a single surgeon over 10 years who
placed endovascular stent grafts in 817 patients at two institutions. There
were 723 AA stent grafts and 94 TA stent grafts. Twelve different devices
were used. Mean patient age was 74.3 years. Based on an intent-to-treat
analysis, the overall technical success rate was 93.8% (94.9% for AA grafts and
85.1% for TA grafts). Type I or III endoleaks occurred in 7% of AA grafts and
15% of TA grafts. Type II endoleaks occurred in 21% of AA grafts and 10%
of TA grafts. Primary clinical success (freedom from aneurysm-related death,
graft infection, thrombosis, rupture, conversion to open repair, or develop-
ment of Type I or Type III endoleak) was 65 6% at 8 years. Device fatigue
occurred in 7.8%. Freedom from aneurysm rupture was 98  1% at 9 years.
Overall survival at 5 years was 47  4%.
Comment: The great discrepancy between clinical success rates (65 
6% at 8 years) and freedom from rupture (98 1% at 9 years) suggests
stent grafts for aortic aneurysmal disease are effective at preventing
aneurysm rupture but at a cost of many secondary procedures. This is a
10-year series. Undoubtedly, clinical success has improved in the more
recent patients. Given the author’s data, and the most recent FDA memo
on endovascular stent grafting for abdominal aortic aneurysms, the
concluding sentence of this report, “While significant advances have
occurred since the initial experiences, additional improvements are es-
sential before [endovascular stent grafting] becomes the standard of
care,” is appropriate.
The association of initial hemodialysis access type with mortality out-
comes in elderly Medicare ESRD patients
Zue JL, Dahl D, Eben JP, Collins AJ. Am J Kidney Dis 2003;42:1013-9.
Conclusion: The type of initial hemodialysis access is associated with
rates of one-year mortality in the US Medicare dialysis population. Mortality
risk is lowest with fistula, intermediate with grafts, and highest with venous
catheters.
Summary: Incident Medicare hemodialysis patients (N  66,595)
who were 67 years of age at time of dialysis initiation were studied with
respective CPT and ICD-9 codes to assess the effect of initial access type on
patient survival. A Cox regression analysis correcting for incidence year, sex,
age, diabetes, race, body mass index, initial access type, days from first access
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